Abstract:KRAS mutations are common in non-small cell lung cancer (NSCLC) and often co-occur with TP53 mutations. Although the KRAS oncogene was once considered 'undruggable,' FDA approval of KRASG12C inhibitors and promising pre-clinical data from KRASG12D inhibitors highlight the potential for targeted therapies. The tumor microenvironment (TME) of NSCLC comprises immune and stromal cells, including antigen-presenting cancer-associated fibroblasts (for simplicity, hereafter 'apCAFs,' regardless of cancer association), a population that expresses markers that interact with and affect T cell activation, exhaustion and differentiation. However, the role of apCAFs in tumorigenesis, how they interact with T cells, and their response to KRAS inhibitors remain unknown. A crucial need exists to characterize apCAFs to optimize therapeutic approaches. We used an inducible and reversible KrasG12D lung cancer mouse model (L-iKras) to perform single cell RNA sequencing analyses. Lung tissue from two each (1 male/1 female) of control mice, mice with KrasG12D turned on with doxycycline (ON), and mice with KrasG12D turned on for 20 weeks and off for 1 week via doxycycline withdrawal (OFF) were included. Fibroblasts were clustered and stratified using the Seurat package. One population resembled apCAFs expressing Pdgfra, Clec3b, Col1a1, and Col1a2 and antigen-presenting markers H2-Ab1, H2-Aa, and Cd74. This population increased in ON and OFF groups compared to controls and expressed genes required for three signals of T cell activation: engagement of the T cell receptor with the peptide- MHC complex of an antigen-presenting cell (APC); binding of costimulatory proteins CD28 or CTLA4 (T cell) with CD80/CD86 (APC); and secreted cytokines (APC) initiating T cell differentiation. This apCAF population showed increased markers for immune checkpoints Cd274 (PDL1) and Cd86, which can inhibit or exhaust T cells, upon KRAS inhibition. Further, these apCAFs upregulated markers involved with the induction of Tregs upon KRAS inhibition (Tgfb1). Treg populations were increased, and CD8 T cell populations were decreased in the OFF group compared to the ON group. These findings suggest that apCAFs are induced in the TME during tumorigenesis and interact with tumor-infiltrating T cells. Further, we hypothesize that apCAFs become immunosuppressive upon KrasG12D inhibition, activate Tregs, and induce CD8 T cell exhaustion. Interestingly, upregulation of immune checkpoints in apCAFs suggests that these cells may respond well to checkpoint therapies, which could be harnessed for future therapeutic approaches in NSCLC. The focus of our future studies will be to validate our findings in an orthotopic lung cancer mouse model developed by our lab, which utilizes KrasG12D-inducible and reversible lung cancer cell lines derived from L- iKras. With this model we will further characterize apCAF-T cell interactions, investigate the impact of KRAS inhibitors on apCAFs, and identify the role of apCAFs in tumor responses to combinations of KRAS inhibitors and checkpoint inhibitors. Citation Format: Rachael Hinshaw, Carlos Espinoza, Yaqing Zhang, Marina Pasca di Magliano, Stefanie Galban. Investigating the role of antigen-presenting fibroblasts in the tumor microenvironment of non-small cell lung cancer [abstract]. In: Proceedings of the AACR Special Conference in Cancer Research: Tumor Immunology and Immunotherapy; 2024 Oct 18-21; Boston, MA. Philadelphia (PA): AACR; Cancer Immunol Res 2024;12(10 Suppl) nr B019.

Late-Breaking Abstract: the Role of Eosinophils in Kras-G12d Induced Lung Tumor Initiation and Progression

Abstract 14566: the Role of Eosinophils in Pulmonary Hypertension

Eosinophils Promote Pulmonary Matrix Destruction and Emphysema Via Cathepsin L

KRAS Mutation Subtypes Responded Differently to Combination Immunotherapy Via Disturbing Myeloid-Derived Suppressor Cells in Non-Small Cell Lung Cancer.

Eosinophils Decrease Pulmonary Metastatic Mammary Tumor Growth

Abstract B016: Eosinophils alter metastatic spread in pancreatic cancer

Exosomal KRAS Mutation Promotes Promotion of Colorectal Cancer by the Formation of Tumor-Associated Neutrophil Extracellular Traps

Eosinophils restrict CRC metastasis by inhibiting pro-tumorigenic SPP1+ macrophage differentiation

IL-17C-mediated Innate Inflammation Decreases the Response to PD-1 Blockade in a Model of Kras-driven Lung Cancer

Abstract B019: Investigating the role of antigen-presenting fibroblasts in the tumor microenvironment of non-small cell lung cancer

Potential Roles of Eosinophils in Cancer Therapy: Epidemiological Studies, Experimental Models, and Clinical Pathology.

Abstract C116: Oncogenic Kras signaling shapes the tumor microenvironment in lung adenocarcinoma

[Research progress on eosinophils in lung cancer]

CCL11/CCR3-dependent eosinophilia alleviates malignant pleural effusions and improves prognosis

Abstract LB359: Lung epithelial specific IL-1R promotes K-ras mutant lung cancer by inducing angiogenesis that might be medicated via myeloid tumor microenvironment

Abstract 1138: A single-cell spatially resolved atlas of immune-mediated control of lung adenocarcinoma using 1,000-plex single-cell spatial molecular imaging in a transgenic mouse model

Lung Pathologies in a Chronic Inflammation Mouse Model Are Independent of Eosinophil Degranulation.

Abstract 5263: The impact of MRTX1133 on anti-tumor immunity in lung cancer with KRASG12D mutation

Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors (Egfr-Tkis) Impact on Immune Microenvironment in Non-Small Cell Lung Cancer (NSCLC).

Frontline Science: Eosinophil-Deficient Mbp-1 and Epx Double-Knockout Mice Link Pulmonary Remodeling and Airway Dysfunction with Type 2 Inflammation

Spatial proteomic analysis of a lung cancer model reveals regulatory T cells attenuate KRAS-G12C inhibitor-induced immune responses